Moderna Scores Another Cash-Rich Partnership For Its Preclinical Work
This article was originally published in The Pink Sheet Daily
Executive Summary
The mRNA-focused company has inked a deal with Alexion for its work in rare diseases, promising plenty of cash in its future and further validation of its technology.